Carsten Denkert
Carsten Denkert
Professor of Pathology, Philipps-University Marburg, Germany
Verified email at uni-marburg.de
Title
Cited by
Cited by
Year
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes
G Von Minckwitz, M Untch, JU Blohmer, SD Costa, H Eidtmann, ...
Journal of clinical oncology 30 (15), 1796-1804, 2012
16792012
An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients
B Györffy, A Lanczky, AC Eklund, C Denkert, J Budczies, Q Li, Z Szallasi
Breast cancer research and treatment 123 (3), 725-731, 2010
16722010
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer
C Denkert, S Loibl, A Noske, M Roller, BM Muller, M Komor, J Budczies, ...
J Clin Oncol 28 (1), 105-113, 2010
11662010
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R Salgado, C Denkert, S Demaria, N Sirtaine, F Klauschen, G Pruneri, ...
Annals of oncology 26 (2), 259-271, 2015
10982015
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
S Loi, S Michiels, R Salgado, N Sirtaine, V Jose, D Fumagalli, ...
Annals of oncology 25 (8), 1544-1550, 2014
7842014
Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization
J Budczies, F Klauschen, BV Sinn, B Győrffy, WD Schmitt, ...
PloS one 7 (12), e51862, 2012
6862012
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative …
C Denkert, G Von Minckwitz, JC Brase, BV Sinn, S Gade, R Kronenwett, ...
J Clin oncol 33 (9), 983-991, 2015
6192015
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
G Von Minckwitz, A Schneeweiss, S Loibl, C Salat, C Denkert, M Rezai, ...
The lancet oncology 15 (7), 747-756, 2014
6122014
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
G Curigliano, HJ Burstein, E P Winer, M Gnant, P Dubsky, S Loibl, ...
Annals of Oncology 28 (8), 1700-1712, 2017
5232017
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer
G von Minckwitz, H Eidtmann, M Rezai, PA Fasching, H Tesch, ...
New England Journal of Medicine 366 (4), 299-309, 2012
4792012
Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy
W Weichert, A Röske, V Gekeler, T Beckers, C Stephan, K Jung, ...
British journal of cancer 98 (3), 604-610, 2008
4432008
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer
M Kaufmann, G Von Minckwitz, EP Mamounas, D Cameron, LA Carey, ...
Annals of surgical oncology 19 (5), 1508-1516, 2012
4072012
Mass spectrometry–based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors
C Denkert, J Budczies, T Kind, W Weichert, P Tablack, J Sehouli, ...
Cancer research 66 (22), 10795-10804, 2006
3952006
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006
M Kaufmann, G Von Minckwitz, HD Bear, A Buzdar, P McGale, H Bonnefoi, ...
Annals of Oncology 18 (12), 1927-1934, 2007
3902007
Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression
M Hilvo, C Denkert, L Lehtinen, B Müller, S Brockmöller, ...
Cancer research 71 (9), 3236-3245, 2011
3622011
Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo
W Weichert, A Röske, S Niesporek, A Noske, AC Buckendahl, M Dietel, ...
Clinical Cancer Research 14 (6), 1669-1677, 2008
3482008
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
C Denkert, G von Minckwitz, S Darb-Esfahani, B Lederer, BI Heppner, ...
The lancet oncology 19 (1), 40-50, 2018
3352018
CD24 expression is a new prognostic marker in breast cancer
G Kristiansen, KJ Winzer, E Mayordomo, J Bellach, K Schlüns, C Denkert, ...
Clinical cancer research 9 (13), 4906-4913, 2003
3342003
Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis
W Weichert, A Röske, V Gekeler, T Beckers, MPA Ebert, M Pross, M Dietel, ...
The lancet oncology 9 (2), 139-148, 2008
3322008
Expression of cyclooxygenase 2 in human malignant melanoma
C Denkert, M Köbel, S Berger, A Siegert, A Leclere, U Trefzer, ...
Cancer research 61 (1), 303-308, 2001
3142001
The system can't perform the operation now. Try again later.
Articles 1–20